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Hepatocellular carcinoma (HCC) is a highly malignant tumor 
with limited treatment options in its advanced state. The mo-
lecular mechanisms underlying HCC remain unclear because 
of the complexity of its multi-step development process. 
Cancer stem cells (CSCs) are deﬁ  ned as a small population 
of cells within a tumor that possess the capability for self-
renewal and the generation of heterogeneous lineages of 
cancer cells. To date, there have been two theories concern-
ing the mechanism of carcinogenesis, i.e., the stochastic 
(clonal evolution) model and the hierarchical (cancer stem 
cell-driven) model. The concept of the CSC has been estab-
lished over the past decade, and the roles of CSCs in the 
carcinogenic processes of various cancers, including HCC, 
have been emphasized. Previous experimental and clinical 
evidence indicated the existence of liver CSCs; however, 
the potential mechanistic links between liver CSCs and the 
development of HCC in humans are not fully understood. 
Although deﬁ  nitive cell surface markers for liver CSCs have 
not yet been found, several putative markers have been 
identiﬁ  ed, which allow the prospective isolation of CSCs from 
HCC. The identiﬁ  cation and characterization of CSCs in HCC 
is essential for a better understanding of tumor initiation or 
progression in relation to signaling pathways. These markers 
could be used along with clinical parameters for the predic-
tion of chemoresistance, radioresistance, metastasis and 
survival and may represent potential targets for the develop-
ment of new molecular therapies against HCC. This review 
describes the current evidence for the existence and function 
of liver CSCs and discuss the clinical implications of CSCs 
in patients demonstrating resistance to conventional anti-
cancer therapies, as well as clinical outcomes. Such data 
may provide a future perspective for targeted therapy in HCC. 
Correspondence to: Seung Kew Yoon 
Division of Hepatology-Gastroenterology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, 505 Banpo-dong, 
Seocho-gu, Seoul 137-701, Korea 
Tel: +82-2-2258-7534, Fax: +82-2-536-9559, E-mail: yoonsk@catholic.ac.kr
Received on May 19, 2011. Accepted on June 18, 2011.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.1.29
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
(Gut Liver 2012;6:29-40)
Key Words: Hepatocellular carcinoma; Stem cell; Cancer 
stem cell
INTRODUCTION
Normal cell turnover occurring continuously in various tis-
sues of a healthy adult human being plays an essential role in 
maintenance of normal tissue function and architecture over 
time through tightly regulated biological processes. Under 
physiological conditions, this dynamic process is sustained by 
a long-lived, small population of cells known as “stem cells,” 
which have three main properties, self-renewal, differentiation, 
and homeostatic control.
1 Malignant tumors, on the other hand, 
are comprised of morphologically diverse cells and phenotypi-
cally heterogenous populations that possess high clonogenic 
and tumorigenic activity, and a varying degree of ability for 
self-renewal and differentiation into multiple cell types.
2-6 Of 
those cells, certain minor cell populations have played an es-
sential role in tumorigenesis; this phenomenon led to the new 
concept of tumor-initiating cells (T-ICs) or cancer stem cells 
(CSCs). CSCs, as defined by the American Association for Cancer 
Research Workshop, denotes cells within a tumor that possess 
the capacity for self-renewal and generation of heterogenous 
lineages of cancer cells that comprise the tumor.
7 In an attempt 
to explain this phenomenon, two different theories have been 
proposed: one is “the stochastic model,” which claims that every 
cancer cell in a tumor can ultimately acquire a capacity for self-
renewal and multilineage potency, and therefore repopulate an 
entire tumor;
8 the other is “the hierarchy model,” which claims 
that every cancer cell in a tumor is heterogenous and that only 
a minority of cells serve as CSC, giving rise to tumors (Fig. 1). 30  Gut and Liver, Vol. 6, No. 1, January 2012
The first evidence for the existence of CSC was revealed in 
a study of acute myeloid leukemia by Bonnet and Dick.
9 They 
found that a subpopulation of leukemia cells expressing a spe-
cific surface marker, CD34, but lacking the CD38 marker (CD34
+/
CD38
-), was capable of initiation and progression of cancer 
in their experimental model; hence, the authors defined these 
cancer cells as CSCs because they possess biological properties 
unique to normal stem cells. However, this hierarchy model ar-
gued against the traditional stochastic theory, suggesting that all 
cells in a tumor have an equally malignant potential for propa-
gation and malignancy.
7,10 Since this hierachial or CSC model 
was first proven in solid tumors of breast cancer by Al-Hajj 
et al.,
11 verifiable evidence for the existence of CSC has been 
reported in numerous solid tumors, including brain,
12 colon,
13 
pancreatic,
14 lung,
15 prostate,
16 liver,
17 melanoma,
18 and ovarian 
cancers.
19 However, cancers do not always follow the hierachial 
manner in development of tumors.
20 In addition, recent works 
have described several factors influencing the two models of 
carcinogenesis, including etiologic mutagens, microenviron-
ment, and type of cancer;
21 hence, further clarification might be 
required in order to understand the role of CSC in tumorigenesis 
of solid tumors.
This review will focus on the role of CSCs in hepatocarcino-
genesis and its clinical implications, including biomarkers, 
chemo/radioresistance, and development of new targeted thera-
pies for treatment of hepatocellular carcinoma (HCC). 
MARKERS FOR IDENTIFICATION OF LIVER CSCs
Identification of tumor specific biomarkers is essential for 
early detection of cancers or development of targeted therapy 
for treatment of cancers. In general, prospective isolation and 
characterization of CSCs are based on their immunogenicity and 
functional properties. Immunogenic isolation is performed us-
ing cell surface markers, while functional isolation is dependent 
on the surrogate characteristics of CSCs, including clonogenic 
growth, formation of tumor spheres, or resistance to chemo/
radiotherapy. Extensive research has been conducted in recent 
years for identification of putative cancer stem cell markers. 
Since identification of the marker for leukemic stem cells (LSCs), 
candidate markers of stem cells for solid tumors have been ex-
plored. Currently, to be identified as a CSC marker for any type 
of tumor, the ability of a candidate marker to initiate the same 
tumor type should be proven in a xenograft model. Although it 
is not yet known whether all cancers possess subpopulations of 
CSCs, several putative CSC markers that have been reported to 
Fig. 1. Two general models for tumorigenesis. The stochastic model claims that every cancer cell in a tumor can ultimately acquire a capacity for 
self-renewal and multilineage potency, thereby forming new tumors (A), whereas the hierarchy model claims that cancer cells in a tumor are het-
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date are summarized in Table 1. However, various cell surface 
markers for CSCs from the same tumor type or the same marker 
in different types of cancers have been reported; therefore, it is 
difficult to define a single marker for CSCs in any tumor. 
The first evidence for the existence of a CSC population in 
the liver was reported by Haraguchi et al.
22 They examined a 
subset of stem cells identified as “side population” (SP) cells 
using the DNA-binding dye Hoechst 33342 in three hepatoma 
cell lines (HepG2, Hep3B, and Huh-7 cell), and found that Huh-
7 and Hep3B cell lines contain SP cells; however, HepG2 cells 
did not show a SP. Subsequent studies have revealed candidate 
markers of liver CSC, including CD90,
17 CD133,
23 epithelial 
cell adhesion molecule (EpCAM),
24 CD44,
25 and CD13.
26 On the 
other hand, CD133 identifies CSCs in certain specific tumors, 
including brain, prostate, colon, pancreas, lung, and ovarian 
cancer.
27 CD90 (Thy-1), a surface marker for many types of stem 
cells, was expressed in HCC cell lines and human liver cancer 
specimens, and CD90
+ HCC cells displayed tumorigenicity in 
a xenograft mice model.
28 In addition, they demonstrated that 
CD90
+CD44
+ cells displayed a more aggressive phenotype than 
CD90
+CD44
- cells, leading to formation of metastatic lesions in 
the lung of immunodeficient mice.
17 CD133, known as a human 
homologue of mouse prominin-1, is a pentaspan transmem-
brane cell surface glychoprotein.
29 Since identification of CD133 
antigen as a hematopoietic stem cell marker, its expression in 
various human embryonic epithelia has been demonstrated. 
Existence of CD133 in HCC cells was first reported by Suetsugu 
et al.,
30 who found CD133 expression in a Huh-7 cell line and 
demonstrated that CD133
+ Huh-7 cells have a higher prolifera-
tive property in vitro and tumorigenic potential in vivo. Charac-
terization of EpCAM, the cell surface hepatic stem cell marker, 
in HCC cells and human HCC samples was initially revealed by 
Yamashita et al.,
24 who demonstrated that EpCAM
+ HCC cells 
possessed the hepatic cancer stem cell-like capabilities for self-
renewal and differentiation. These cells also displayed a po-
tential for initiation of highly aggressive and invasive HCC in 
an immunodeficient experimental mice model. Most recently, 
Haraguchi et al.
26 reported that CD13 is a marker for semiquies-
cent CSCs in human liver cancer cell lines and clinical samples. 
Although several markers for identification and characterization 
of hepatic CSCs have been reported, a single cell surface marker 
has a limitation in its ability to define fully specific CSCs in any 
tumor. For this reason, many researchers have attempted to find 
other cell surface molecules in order to more precisely define the 
CSC subpopulation for a better understanding of hepatocarcino-
genesis. Zhu et al.
25 showed that co-expression of CD44 antigen 
in addition to CD133 in HCC cells represented more precise stem 
cell properties of CSCs, including self-renewal, differentiation, 
and aggressive proliferation. Taken together, various approaches 
to isolation and characterization of CSCs in HCC that allow 
for enrichment of hepatic CSCs have been explored, and these 
markers could be used along with clinical parameters for predic-
tion of prognosis as well as providing a better understanding of 
tumor initiation or progression in HCC. 
ROLE OF CSCs IN HEPATOCARCINOGENESIS
HCC is one of the most common malignancies worldwide and 
the third leading cause of cancer-related death. Common risk 
factors for development of HCC, including presence of liver cir-
rhosis irrespective of cause, chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infections, chronic ethanol consumption, 
nonalcoholic steatohepatitis (NASH) and aflatoxin B1 (AFB1) 
have been well recognized.
31 
In general, hepatocyte necrosis followed by regeneration dur-
ing chronic liver injury leads to liver cirrhosis. In the tissue of 
liver cirrhosis, stepwise hepatocyte transformation begins and 
then finally progresses to HCC via a series of hyperplastic and 
dysplastic stages. This concept of hepatocarcinogenesis has long 
been regarded as a multistep process associated with accumula-
tion of genetic and epigenetic changes that pass through steps 
of initiation, promotion, and progression. However, occurrence 
of these genetic or molecular events accompanying alterations 
of cell cycle, differentiation, and apoptosis is dependent on the 
risk factors; therefore, a complete understanding of hepatocar-
cinogenesis is more difficult. Extensive research in recent de-
cades has focused on identification of molecular biomarkers and 
cellular signaling pathways involved in development of HCC. 
Table 1. Cancer Stem Cells Markers Identified in Various Cancers
Tumor type CSC marker Reference
Acute myeloid leukemia  CD34
+CD38
-   9
Breast CD44
+CD24
-/low 11
Breast ALDH1
+ 83
Brain CD133
+ 12
Colon CD133
+ 13
Colon EpCAM
high CD44
+ 84
Head and neck  CD44
+ 85
Prostate CD44
+ α2β1
high CD133
+ 16
Melanoma ABCB5
+ 18
Lung CD133
+ 15
Liver CD90
+ 17
Liver CD133
+ 23
Liver EpCAM 24
Liver CD13 26
Ovary CD44
+ CD117
+ 86
CSC, cancer stem cell; EpCAM, epithelial cell adhesion molecule; 
ABCB5, adenosine triphosphate-binding cassette sub-family B mem-
ber 5.32  Gut and Liver, Vol. 6, No. 1, January 2012
In a number of previous studies, various signaling pathways, 
including p53, retinoblastoma protein (pRb), Wnt/β-catenin, Ja-
nus kinases (JAK)/signal transducers, mitogen-acivated protein 
kinase (MAPK), epidermal growth factor receptor transforming 
growth factor-β (EGF/TGF-β) pathways, stress response signal-
ing, and activators of transcription (STAT), have been found to 
contribute to hepatocarcinogenesis.
31 More recently, we dem-
onstrated that SOX4 protein interacts with p53 and that this 
association in turn modulates p53-mediated transcription at the 
Bax promoter, leading to inhibition of apoptosis via suppression 
of Bax gene expression.
32 
So-called oval cells proposed in the past by several investiga-
tors are located in the Canals of Hering and have been recog-
nized as putative hepatic stem/progenitor cells (HPCs) giving 
rise to hepatocytes and cholangiocytes.
33 In general, hepatoytes 
and cholangiocytes contain cytoskeletal intermediate filaments, 
called cytokeratins (CK) which is differentially expressed de-
pending on the organ or the type of differentiation. In normal 
liver, the combination of CK8 and CK18 was expressed in hepa-
tocytes while that of CK7 and CK19 was expressed in cholan-
giocytes and bipotential (HPCs).
34-36  
To date, the question about the cellular origin of HCC is still 
debated. There are two major hypotheses regarding the origina-
tion of HCC: 1) from dedifferentiation of mature hepatocytes or 2) 
from the block of stem cell differentiation. Bralet et al.
37 demon-
strated that some of mature hepatocytes gave rise to HCC in the 
chemically induced rat HCC model. In general, extracellular ma-
trix (ECM) is known to important mediator in the process of liv-
er fibrogenesis but it has two-edged roles of inhibitor and pro-
moter in the carcinogenesis and progression of HCC. Fibroblast 
derived ECM inhibit tissue-specific gene expression in fetal and 
adult hepatocytes.
38 ECM remodeling in cirrhosis inhibits the 
transactivation potential of liver-specific transcription factors in 
hepatocytes, resulting in dedifferentiation of hepatocytes lead-
ing to development of HCC.
39 In addition, previous experimental 
data provided an evidence that small hepatocyte-like progenitor 
cells were activated and differentiated when the proliferation 
of hepatocytes was suppressed after partial hepatectomy in rats 
treated with pyrrolizidine alkaloid retrosine, suggesting that the 
dedifferentiation of mature hepatocytes occurs when the pro-
liferation is suppressed.
40 However, it is interesting to note the 
cellular origin of HCC in the case of human HCC samples show-
ing the presence of cells expressing CK7 and CK19. It might 
be originated from dedifferentiation of mature hepatocytes to 
HPCs or from a maturation arrest of HPCs during carcinogenic 
process.
41,42 Recently, evidence is growing that HPCs as well as 
mature hepatocytes can give rise to HCC. Recent studies have 
described involvement of HPCs in hepatocarcinogenesis via ac-
tivation and proliferation in response to liver injury in a chemi-
cally-induced HCC rodent model.
43,44 Furthermore, Theise et al.,
45 
confirmed the existence of HPCs in human liver cancers, sug-
gesting that some liver cancers originate from HPCs. These re-
sults support the concept that human hepatocarcinogenesis can 
be based on transformation of HPCs. Therefore, a fundamental 
understanding of the characteristics of HPCs may provide in-
sight into the carcinogenic process of the liver while it is occur-
ring. The oval cells are activated and proliferate in premalignant 
hepatic lesions induced by chronic liver injury; therefore, it 
is possible to postulate that HPCs could serve as CSC in HCC. 
Proliferation of HPCs has also been referred to as a “ductular 
reaction,” which was directly associated with the severity of the 
underlying premalignant liver disease.
46,47 Regarding the fact 
that HCC is evolved from focal precusor lesions, recent studies 
have revealed that activation of HPCs produces a foci of small 
cell dysplasia, suggesting that they play a major role in histo-
genesis of HCC.
48,49 Further mutation occurring during clonal 
expansion leads to progression to low grade dysplastic nodules 
and high grade dysplastic nodules, eventually resulting in HCC. 
In order to further demonstrate the hypothesis that HCC is origi-
nated from HPC, tumor cells should express markers that are 
specifically expressed on HPCs, including OV-6, CK7 and CK19, 
and chromogranin-A.
50 Cells possessing the HPC phenotype 
are often found in hepatoblastoma, which is the most common 
childhood liver cancer.
51 This tumor, as a fetal-like liver cancer 
comprising epithelial and mesenchymal components, is believed 
to originate from liver stem cells. On the other hand, the ductu-
lar reaction in human liver, which is comparable to the oval cell 
reaction in an experimental model of hepatocarcinogenesis, ap-
pears to be a response to acute or chronic liver injury, including 
viral hepatitis, massive hepatic necrosis, cholestatic liver disease, 
biliary obstruction, and alcoholic liver disease.
52 Hepatocyte-like 
cells found in this reaction co-expressed hepatocytic and biliary 
specific antigen (HepPar1 and CK19, respectively), suggesting 
that ductular hepatocytes recapitulate the developmental stages 
of bipotential liver progenitor cells.
53 Regarding origin of HCC, 
previous studies have demonstrated that markers specific to HPC 
were expressed in some hepatic malignancy, which was com-
posed of two components: an HCC component and a cholangio-
carcinoma component, indicating that this tumor may originate 
from a bipotential progenitor.
45 However, because HBV can 
induce carcinogenesis via direct integration of the viral genome 
into host cell DNA in HBV-related HCC, CSCs in many different 
liver cancers cannot simply be regarded as being derived from 
HPCs. 
Key signaling pathways that regulate the function of CSCs, 
such as Wnt/β-catenin, TGF-β, Hedgehog, Notch, and MYC, 
have been recently been revealed by recent advances in mo-
lecular techniques. Therefore, further study would be required 
in order to obtain convincing evidence for the origin of liver 
cancer. 
Among signaling pathways regulating CSCs, key signal-
ing pathways have been implicated in development of HCC. 
Recently, Yamashita et al.
24,54 demonstrated that activation of 
Wnt/β-catenin signaling enriched the EpCAM
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tion whereas inhibition of EpCAM using si RNA decreased the 
biologic properties of hepatic CSCs, indicating that EpCAM is 
a Wnt/β-catenin signaling target gene (Fig. 2). A study of the 
role TGF-β in HCC showed correlation of its late expression 
signature with more invasive tumor characteristics and poor 
clinical outcome, including metastasis and survival.
55 In a recent 
work by Tang et al.,
56 HCC was found to arise from interleukin 
(IL)-6 driven transformed stem cells with inactivated TGF-β 
signaling. They provided evidence to show that development of 
HCC may occur via dysregulated proliferation of HPCs under 
conditions in which the function of TGF-β was disrupted. The 
Notch and Hedgehog signaling pathways play an essential role 
in embryogenesis and regulation of cellular processes, includ-
ing proliferation, angiogenesis, and self-renewal. Gao et al.
57 
recently examined expression of the Notch receptor in human 
HCC samples. They found that Notch1 and Notch4 were up-
regulated; however, Notch2 was down-regulated, suggesting 
that Notch signaling might be involved in development of HCC. 
A recent study by Ma et al.
23 showed preferential expression of 
specific genes closely linked with self-renewal, differentiation, 
and proliferation of stem cells, such as Wnt/β-catenin, Notch1, 
smoothened (SMO)/Hedgehog, Oct-3/4, and Bmi in CD133
+ HCC 
cells (Fig. 2). These results suggest that targeting of these critical 
pathways in regulation of CSCs may be a promising tool for use 
in complete eradication of tumor cells. 
CLINICAL IMPLICATIONS OF LIVER CSCs
1. Role of liver CSCs in chemoresistance
To date, the precise mechanism underlying chemoresistance, 
radioresistance, and tumor recurrence in different cancers is not 
yet clear. Furthermore, the exact reason for why the response 
to anticancer therapies was different even in the same type of 
cancer from different patients remains unclear. However, the 
biological and molecular features of CSCs within tumors, in-
cluding diverse regulatory mechanisms and signaling pathways, 
Fig. 2. The signaling pathways linked to hepatic cancer stem cells (CSCs) in hepatocarcinogenesis. Key signaling pathways that regulate the func-
tion of hepatic CSCs include Wnt/β-catenin, transforming growth factor (TGF-β), Hedgehog, Notch, and MYC. Epithelial cell adhesion molecule 
(EpCAM) is a Wnt/β-catenin signaling target gene, and activation of Wnt/β-catenin signaling regulates EpCAM expression in hepatocellular car-
cinoma (HCC) cell lines. In CD133
+ HCC cells, Wnt/β-catenin, Notch1, and smoothened (SMO)/Hedgehog signaling pathways are linked with self-
renewal, differentiation, and proliferation of hepatic CSCs. Targeting of these critical pathways in the regulation of hepatic CSCs may be a promis-
ing tool for the development of new therapies to eradicate tumor cells completely in HCC. 
Gli3, glioma-associated oncogene family zinc finger 3; TACE, TNF-alpha converting enzyme; PTC, patched.34  Gut and Liver, Vol. 6, No. 1, January 2012
may contribute to cancer cell survival. Although not all types 
of malignancies follow the hierarchical theory (CSC hypoth-
esis), it might explain the reason why conventional anti-cancer 
therapies have shown such resistance. In general, conventional 
external beam radiotherapy or anticancer chemotherapy target 
proliferating cells and require cycling of cells to induce apop-
tosis. Therefore, it is plausible that CSCs containing a quiescent 
nature have inherent resistance to conventional therapies. In 
other words, rapidly proliferating cells can be killed with anti-
cancer drugs while a quiescent slow-cycling stem cell popula-
tion can escape therapeutic targeting, leading to recurrence of 
tumors.
58 Furthermore, once chemotherapy-resistant CSCs re-
enter the cell cycle, they generate rapidly dividing progenitor 
cells with the ability to reestablish the tumor. In addition, recent 
works have suggested several mechanisms for chemoresistance 
by CSCs. Adenosine triphosphate (ATP)–binding cassette (ABC) 
transporters commonly expressed on cellular membranes of 
both normal stem cells and CSCs include multidrug resistance 
transporter 1 (MDR1) and breast cancer resistance protein (BCRP) 
drug transport pumps and play an essential role in expelling an-
ticancer drugs from cells, leading to chemoresistance.
59 Another 
study reported on involvement of CSCs expressing aldehyde 
dehydrogenase 1 (ALDH1), which facilitates metabolism, in 
chemoresistance.
60 SP cells, identified by Haraguchi et al.,
22 have 
some characteristics of stem cells, and were found to express 
higher chemoresistance when compared with non-SP cells. In 
particular, Huh-7 SP cells expressing ABC transporters, such as 
MDR1 and BCRP1, showed chemoresistance to doxorubicin. In 
addition, Huh-7 SP cells were found to overexpress CEACAM6, 
which was known to be associated with chemoresistance to 
gemcitabine.
61 Regarding the role of CD133 in development of 
HCC, CD133-expressing cancer cells are not only responsible 
for tumor initiation or progression, but also have stem cell-
like properties, like colony-forming ability and differentiation 
potential.
23 Moreover, Ma et al.
62 recently demonstrated that 
CD133
+ HCC cells contribute to chemoresistance through pref-
erential activation of Akt/PKB and Bcl-2 cell survival response. 
More recently, Haraguchi et al.
26 demonstrated that CD13 is a 
Fig. 3. The roles of hepatic cancer 
stem cells (CSCs) in tumorigenesis 
and treatment resistance in hepatocel-
lular carcinoma. Normal stem cells 
self-renew and can differentiate into 
progenitor cells, which eventually 
differentiate into fully differentiated 
hepatocytes. CSCs can arise from 
normal stem cells, progenitor cells 
and even differentiated hepatocytes 
when oncogenic events occur during 
cellular processes. The expansion of 
hepatic CSCs results in the forma-
tion of the primary tumor, which is 
composed of a heterogeneous mass of 
cancer cells. The unlimited prolifera-
tion of hepatic CSCs promotes tumor 
growth and can give rise to distant 
metastases that occur in conjunction 
with the angiogenic process. When 
chemotherapy or radiotherapy is used, 
hepatic CSCs play an essential role in 
treatment resistance and can produce 
tumor recurrence.Yoon SK: The Biology of Cancer Stem Cells and Its Clinical Implication in Hepatocellular Carcinoma  35
marker for semiquiescent CSCs in human liver cancer cell lines 
and that CD13 predominated in the G0 phase of the cell cycle, 
decreased reactive oxygen species (ROS)-induced DNA damage 
after genotoxic chemo/radiation stress, and protected cells from 
apoptosis. Taken together, these results suggest that last surviv-
ing CSCs during anti-cancer chemotherapy can lead to tumor 
regrowth or recurrence via their enhanced chemoresistance (Fig. 
3).  
2. Role of liver CSCs in radioresistance 
Radiotherapy is aimed at destruction of cancer cells, which 
prevents tumor growth without damaging normal tissues 
around the tumor. Although radiation therapy has been widely 
used for curative or palliative therapy in various cancers, tumor 
recurrence is inevitable in such cases due to radioresistance. In 
this regard, extensive research has been conducted for investi-
gation of the mechanisms of radioresistance in different can-
cers; however, to date, the mechanisms underlying development 
of radioresistance remain elusive. Recent evidence has accumu-
lated to suggest correlation of the CSC-population with higher 
radioresistance compared with the non-CSC population.
63,64 A 
study by Bao et al.
63 focused on the role of putative CSCs in 
radioresistance in malignant gliomas. Glioma cells expressing 
CD133 were much more radioresistant than glioma cells lacking 
CD133 and survived ionizing radiation in increased proportions. 
In general, check point kinases, like Chk1 and Chk2, become 
activated during genotoxic stress in initiation of cell cycle ar-
rest. They demonstrated that DNA damage check point response 
was more predominantly activated in CD133
+ glioma cells, 
compared with CD133
- glioma cells, suggesting that CD133-
expressing cells contributed to radioresistance through activa-
tion of checkpoint response and repair mechanisms in response 
to DNA damage by radiation. Thus, inhibition of Chk1/2 kinases 
may disrupt the radioresistance of CSC-enriched cells, thereby 
providing a therapeutic advantage to reducing raioresistance of 
CSC. In another study using a breast cancer model, Phillips et 
al.,
64 demonstrated that CD24
-/low/CD44
+ cancer-initiating cells 
isolated from breast cancer cell lines (MCF-7 and MDA-MB-231) 
are relatively radioresistant and increase in numbers after 
short courses of fractionated irradiation. Also, levels of reac-
tive oxygen species and phosporylation of histone H2AX were 
decreased in a mammosphere culture. Furthermore, recent work 
by Woodward et al.
65 suggests that the Wnt/β-catenin signaling 
pathway may be considered as one mechanism of radioresis-
tance in breast cancer. They showed that progenitor cells in the 
mammary gland were more resistant to clinically relevant doses 
of radiation than nonprogenitor cells and that overexpression 
of the Wnt/β-catenin pathway enhanced the radioresistance of 
progenitor cells. In addition, radiation induced enrichment of 
SP progenitors in the human breast cancer cell line. Thus, these 
results suggest involvement of the Wnt/β-catenin SP in radiore-
sistance in mammary progenitor cells as well as cells expressing 
CSC markers in breast cancer. In addition, several pathways 
implicated in radioresistance of CSC populations in various 
cancers have been proposed by recent works: Notch pathway,
64 
Hedgehog-Gli1 pathway,
66 a pathway downstream of EGFR,
67 
and loss of the tumor suppressor PTEN.
68 
In general, hypoxia in tumors has been reported to have an 
association with chemoresistance and radioresistance.
69 Tran-
scription factor hypoxia inducible factor-1 (HIF-1) is activated 
in response to hypoxic stress on cells. HIF-1 activated by hy-
poxic damage in tumor cells following radiotherapy promotes 
expression of genes that allow tumor cells to survive, leading to 
development of radioresistance.
70 However, studies addressing 
radioresistance in hypoxic CSCs after radiotherapy have been 
limited. Although it is not as yet entirely clear how hypoxia af-
fects stemness of CSC, it might affect stem cell generation and 
maintenance in tumors through activation of HIFs.
71 In addition, 
radioresistant hypoxic cells have the opportunity to reoxygenate 
before the next fraction, allowing CSCs to undergo differentia-
tion.
72
To date, there have been few reports regarding the underlying 
mechanism of radioresistance of CSC in HCC. However, recent 
work by Haraguchi et al.
26 showed that CD13 reduced ROS-
induced DNA damage after radiation therapy and protected cells 
from apoptosis in HCC cell lines, suggesting that a combination 
of a CD13 inhibitor with ROS-inducing radiation therapy may 
result in improved treatment of liver cancer. 
3. Role of liver CSCs in clinical outcomes
In recent years, many clinical investigators have attempted to 
determine whether the existence of CSCs is associated with clin-
ical outcomes in solid cancers. Although considerable evidence 
has not emerged, the clinical relevance of CSC remains a major 
challenge for current anti-cancer therapy. To date, numerous 
clinical and experimental studies have shown the association 
between expression of specific genes and clinical outcomes, 
including metastasis, survival, cancer relapse, and disease pro-
gression. However, few studies have shown a correlation with 
clinical outcomes dependent on the existence of CSCs in a 
given malignancy. Nonetheless, several important studies have 
provided evidence showing that hepatic stem/progenitor cell 
markers could predict the prognosis of HCC patients. Through 
comparative genomic investigations in both human and animal 
models, Lee et al.
73 demonstrated that individuals with HCC who 
showed expression of markers for fetal progenitor cells had a 
poor prognosis. In another study, HCC expressing EpCAM and 
alpha-fetoprotein (AFP) characterized by Wnt/β-catenin signal-
ing activation was associated with poor survival.
24 In addition, a 
recent study by Song et al.
74 showed correlation of CD133
+ HCC, 
characterized by higher proliferating properties and greater 
ability to induce tumor formation, with advanced tumor stages, 
poor survival, and tumor recurrence. In addition, CK7 and CK19, 
known to be markers for early hepatoblasts and mature HPCs, 36  Gut and Liver, Vol. 6, No. 1, January 2012
have also been reported to have an association with postopera-
tive tumor recurrence due to its aggressive tumor characteristics, 
like invasiveness.
75
Taken together, although the significance of hepatic stem/
progenitor signature on clinical outcome has been recognized 
in a clinical base, further extensive experimental and clinical 
research should be conducted in order to determine a future 
therapeutic plan after primary treatment for HCC.
THERAPEUTIC STRATEGIES TARGETING LIVER CSCs
Solid tumors, including HCC, are major health burdens 
worldwide and present a major therapeutic challenge. However, 
no traditional anti-cancer therapies for complete eradication of 
cancer cells have been developed to date. Furthermore, because 
this traditional anti-cancer therapy primarily targets rapidly 
dividing cells, it could not eradicate CSCs in tumors, and, as a 
drawback, it also affects rapidly dividing healthy cells. There-
fore, exploration of new anti-cancer therapies that disrupt criti-
cal “stemness” pathways regulating self-renewal, pleuripotency, 
chemoresistance, radioresistance, and angiogenesis is essential.
7 
Nowadays, since introduction of the concept of CSCs in differ-
ent tumors, there have been many advances in the unraveling 
of cancer pathophysiology, including tumor angiogenesis, me-
tastasis, and resistance to chemotherapy/radiotherapy. In addi-
tion, accumulating evidence suggests that epigenetic regulation, 
microRNA, and tumor microenvironment play key roles in reg-
ulation of stem cell self-renewal.
76 In addition, since candidate 
cell surface markers for CSCs have been identified and char-
acterized in various cancers, the paradigm for cancer therapy 
may be changed to target therapy for CSCs. Furthermore, recent 
research has suggested that evolving strategies for targeted 
cancer therapy aim at effective targeting of CSCs, but not non-
CSCs, because normal stem cells have been more sensitive than 
CSCs in response to chemotherapy.
77 Thus, a highly qualified 
assay system for specific purification and characterization of 
CSCs should be developed for use in CSC-targeting drug dis-
covery. Currently, the therapeutic strategies for targeting CSCs 
have been developed through suppressing tumor growth, induc-
ing apoptosis and enhancing differentiation via blockade of 
CSC pathway, disrupting microenvironment and increasing the 
sensitivity to chemotherapy or radiotherapy. To this end, small 
molecule inhibitors, fusion proteins and viral-mediated gene 
therapy have been used. However, the clinical application of the 
small molecule inhibitors have remained limited for the reasons 
like lower specificity and serious adverse effect.
78 On the other 
hand, virus-mediated gene therapy targeting CSC pathway has 
offered some potential therapeutic advantages over proteins- or 
small molecule inhibitors-based therapies in terms of long-term 
therapeutic efficacy without drug resistance.
66 However, the im-
munogenicity of viral vectors is yet to be resolved.   
To date, several surface markers for liver CSCs, including 
CD90, CD133, EpCAM, CD44, and CD13 have been reported. 
These markers may be powerful targets for use in development 
of targeted drugs for treatment of HCC. Among previous studies 
focusing on characterization of liver CSCs, Yang et al.,
17 found 
that CD90
+CD44
+ HCC cells have a more aggressive tumor phe-
notype and stronger metastatic potential than CD90
-CD44
- HCC 
cells, and demonstrated that inhibition of CD44 with antibody 
induces the death of aggressive CD90
+ HCC cells, resulting in 
prevention of local and metastatic tumor formation. These 
results suggest that CSCs-targeting therapeutic approaches in-
volving destruction of CD90
+CD44
+ liver CSCs may offer prom-
ise for use in HCC treatment. In another study, EpCAM
+ HCC 
cells showed Wnt/β-catenin signaling activation and EpCAM 
blockade with siRNA, resulting in significant attenuation of 
both tumorigenic and invasive potential of liver CSCs.
24 These 
results suggest that targeting of Wnt/β-catenin signaling, which 
is downstream of EpCAM, may therefore provide an attractive 
therapy for treatment of HCC. In addition, a more recent study 
by Haraguchi et al.
26 suggested CD13, a marker for semiquies-
cent CSCs in human HCC cell lines, as a therapeutic target for 
liver CSCs. In their study, CD13 reduced ROS-induced DNA 
damage following genotoxic stress, such as a chemotherapeu-
tic agent or radiation treatment, resulting in protection of cells 
from apoptosis. Inhibition of CD13 suppresses self-renewal and 
proliferation of tumor-initiating liver CSCs, suggesting that a 
combination of ROS-inducing chemotherapy with CD13 in-
hibitor may be a promising approach to chemoresistant HCC. 
However, because the biological characteristics of liver CSCs, in-
cluding their heterogeneity and hierarchy, comprise a complex 
nature, further characterization of liver CSCs function should 
be clarified for development of targeted drugs for treatment of 
HCC.
CONCERNS ABOUT CANCER STEM CELL-TARGETED 
THERAPY
Although cancer stem cell-targeted therapy has strong poten-
tial to eliminate CSCs, some problems are yet to be resolved. It 
has been known that normal stem cells and CSCs share several 
common biological properties.
8 In particular, because some 
signaling pathways for survival, such as Wnt/β-catenin, Notch, 
Hedgehog, Bmi-1
79 are shared in both cells, the cellular damages 
on normal stem cells would be expected to occur soon if CSC-
target therapy centered on these pathways. Thus, in order to 
reduce the risk of such cellular damage, it is essential to select 
the signaling pathway which is exclusively expressed on CSCs 
for targeting sites. For instance, EpCAM known as CSC marker 
plays an essential role in cellular proliferation, migration and 
mitogenic signal transduction.
80 However, EpCAM in normal 
cells is also predominantly expressed in intercellular spaces 
where epithelial cells form very tight junctions and function a 
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dition, Wnt signaling pathway which regulates cellular process-
es in tumor development, also plays a key role in maintenance 
of homeostasis in mature tissues.
81 Therefore, the physiology of 
normal cells may be changed when trying to target them. None-
theless, recent study by Yilmaz et al.
82 demonstrated successful 
targeted therapy without damaging normal stem cell in leuke-
mia. In the experiment, they used Rapamycin to suppress the 
activation of Akt-mTOR pathway resulting from PTEN deletion 
in leukemic stem cells, showing that Rapamycin depleted LSCs 
but restored normal hematopoietic stem cell function. However, 
to date, little information is only available about the natures of 
the biological properties regulating signaling pathways in both 
cancer and normal stem cells. The characteristic difference be-
tween both cells need to be elucidated to provide new therapeu-
tic target.  
CONCLUSIONS AND FUTURE PERSPECTIVES
Compared with other vital organs, the liver is a unique or-
gan in terms of regeneration potential. Even though the liver is 
removed by partial hepatectomy or is injured by various nox-
ious stimuli, such as virus toxins, the liver has the capacity for 
renewal of hepatocytes from HPCs, leading to restoration of its 
size and function. However, unlike benign liver diseases, HCC 
comprises a complex pathogenesis linked to many signaling 
pathways with or without involvement of liver CSCs. Although 
previous experimental and clinical works have indicated the 
existence of liver CSCs, potential mechanistic links between 
liver CSCs and development of HCC in human are not fully 
understood. Nonetheless, accumulating evidence supports the 
suggestion that generation of multiple lineage cells by liver 
CSCs in a hierarchical manner is responsible for tumor initia-
tion, metastasis, and relapse after anti-cancer therapy in HCC. 
However, some of the surface markers for normal stem cells and 
CSCs in the liver are overlapped; thus, it is not easy to distin-
guish them by simple methods. Indeed, an inappropriate attack 
by the newly developed targeted drug for CSCs against normal 
stem cells could result in a serious life-threatening disaster. 
Thus, in order to distinguish liver CSCs from normal stem cells, 
development of a highly qualified assay system composed of 
both antigenic and functional approaches for isolation, purifica-
tion, and characterization of CSCs should be required. In fact, 
conventional chemo/radiotherapy can reduce or destroy tumor 
bulk but cannot completely eradicate rare CSCs within a tumor. 
Thus, in order to develop more effective anti-cancer therapy for 
avoidance of chemo/radioresistance for HCC, further investiga-
tion based on biological properties of liver CSCs should be per-
formed at the levels of cells, in vivo and human. 
Although recent evidence has demonstrated that a certain 
type of HCC is hierarchically organized by CSCs, current re-
search findings have not completely clarified the way in which 
liver CSCs initiate tumor growth. Nonetheless, it may help to 
explain the mechanism of chemo/radioresistance and tumor re-
currence after treatment for HCC. Novel therapeutic approaches 
for treatment of HCC should be based on CSC-specific target-
ing using surface markers for liver CSCs, such as CD90, CD133, 
EpCAM, CD44, and CD13. Furthermore, combination therapy 
using conventional methods with specific CSCs-targeted therapy 
for suppression or destruction of CSCs may be a more integrated 
therapeutic approach for treatment of HCC. Further studies in 
the future are needed in order to clarify the exact nature of 
CSCs for unraveling the mechanism underlying HCC.
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